151 related articles for article (PubMed ID: 15516935)
1. Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation.
Woywodt A; Haubitz M; Buchholz S; Hertenstein B
Bone Marrow Transplant; 2004 Dec; 34(12):1015-23. PubMed ID: 15516935
[TBL] [Abstract][Full Text] [Related]
2. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms.
Palomo M; Diaz-Ricart M; Carbo C; Rovira M; Fernandez-Aviles F; Escolar G; Eissner G; Holler E; Carreras E
Biol Blood Marrow Transplant; 2009 May; 15(5):537-46. PubMed ID: 19361745
[TBL] [Abstract][Full Text] [Related]
3. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation.
Palomo M; Diaz-Ricart M; Carbo C; Rovira M; Fernandez-Aviles F; Martine C; Ghita G; Escolar G; Carreras E
Biol Blood Marrow Transplant; 2010 Jul; 16(7):985-93. PubMed ID: 20167280
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelium as 'novel' target of graft-versus-host disease.
Tichelli A; Gratwohl A
Best Pract Res Clin Haematol; 2008 Jun; 21(2):139-48. PubMed ID: 18503982
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Markers of endothelial function in pediatric stem cell transplantation for acute leukemia.
Luzzatto G; Cella G; Messina C; Randi ML; Sbarai A; Zanesco L
Med Pediatr Oncol; 2003 Jan; 40(1):9-12. PubMed ID: 12426679
[TBL] [Abstract][Full Text] [Related]
7. Interplay of Inflammation and Endothelial Dysfunction in Bone Marrow Transplantation: Focus on Hepatic Veno-Occlusive Disease.
Vion AC; Rautou PE; Durand F; Boulanger CM; Valla DC
Semin Thromb Hemost; 2015 Sep; 41(6):629-43. PubMed ID: 26305238
[TBL] [Abstract][Full Text] [Related]
8. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelium and graft-versus-host disease.
Biedermann BC
Best Pract Res Clin Haematol; 2008 Jun; 21(2):129-38. PubMed ID: 18503981
[TBL] [Abstract][Full Text] [Related]
10. Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice.
Zeng L; Yan Z; Ding S; Xu K; Wang L
Transplant Proc; 2008 Oct; 40(8):2670-3. PubMed ID: 18929832
[TBL] [Abstract][Full Text] [Related]
11. Early complications following haematopoietic SCT in children.
Miano M; Faraci M; Dini G; Bordigoni P;
Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S39-42. PubMed ID: 18545243
[TBL] [Abstract][Full Text] [Related]
12. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation.
Cooke KR; Jannin A; Ho V
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):23-32. PubMed ID: 18162218
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
14. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of ADAMTS13 enzyme and its relationship with clinical events after allogeneic hematopoietic stem cell transplantation.
Bozdag SC; Gunaltay S; Dalva K; Ozcan M
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):165-9. PubMed ID: 19657314
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation.
Nachbaur D; Schumacher P; Auberger J; Clausen J; Kircher B
Biol Blood Marrow Transplant; 2007 Aug; 13(8):942-7. PubMed ID: 17640598
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
[TBL] [Abstract][Full Text] [Related]
18. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
[TBL] [Abstract][Full Text] [Related]
19. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
20. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis.
Statkute L; Oyama Y; Barr WG; Sufit R; Ho S; Verda L; Loh Y; Yaung K; Quigley K; Burt RK
Ann Rheum Dis; 2008 Jul; 67(7):991-7. PubMed ID: 17947303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
